Abstract: The present disclosure relates to a crystallization method of branched-chain amino acids capable of sustainably cycling ammonia, and branched-chain amino acid crystal produced by the method.

Abstract: A composition including a plurality of quantum dots; a binder polymer; a thiol compound having at least two thiol groups; a polyvalent metal compound; a polymerizable monomer having a carbon-carbon double bond; a photoinitiator; and a solvent.

Abstract: A display panel including a wavelength conversion structure that includes a base structure including partition walls that define a first space and a second space, a first quantum dot composite disposed in the first space, and a second quantum dot composite disposed in the second space. The height of the partition wall is greater than or equal to about 5 micrometers and less than or equal to about 50 micrometers, and the first quantum dot composite provides a first top surface and the second quantum dot composite provides a second top surface. A production method for making the wavelength conversion structure uses a first ink composition that includes first quantum dots and a first matrix, and a second ink composition that includes second quantum dots and a second matrix.

Abstract: A quantum dot-polymer composite including a polymer matrix; and core-shell quantum dots dispersed in the polymer matrix, wherein the core-shell quantum dots include a semiconductor nanocrystal core including indium, zinc, and phosphorus and a semiconductor nanocrystal shell disposed on the semiconductor nanocrystal core, the shell including zinc, selenium, and sulfur. The core-shell quantum dots do not include cadmium, the core-shell quantum dots are configured to emit green light, the core-shell quantum dots have a mole ratio of phosphorus to indium of greater than or equal to about 0.75, and the core-shell quantum dots have a mole ratio of zinc to indium of greater than or equal to about 35, and a method of producing the core-shell quantum dots, and a display device including a light emitting element that includes the quantum dot-polymer composite.

Abstract: An electronic device includes a first substrate, a plurality of light emitting elements each having a horizontal length and a vertical length which are less than or equal to about 10 micrometers (?m), each of the plurality of light emitting elements being disposed on the first substrate, a quantum dot color filter layer disposed on the plurality of light emitting elements, and a first overcoat layer between a plurality of light emitting elements and the quantum dot color filter layer. The quantum dot color filter layer includes a plurality of quantum dot color filters partitioned by a plurality of first partition walls so as to be overlapped with the plurality of light emitting elements, respectively.

Abstract: A quantum dot-polymer composite pattern including at least one repeating section configured to emit light of a predetermined wavelength, and a production method and a display device including the quantum dot-polymer composite are disclosed. The quantum dot-polymer composite includes a polymer matrix including linear polymer including a carboxylic acid group-containing repeating unit and a plurality of cadmium-free quantum dots dispersed in the polymer matrix, has an absorption rate of greater than or equal to about 85% for light at wavelength of about 450 nm, and has an area ratio of a hydroxy group peak relative to an acrylate peak of greater than or equal to about 2.6 in Fourier transform infrared spectroscopy.

Abstract: The present disclosure relates to a pH-sensitive polymer with a hydrophilic amino acid, a hydrophobic amino acid, and a fatty acid, a coating composition, and a feed additive coated with the coating composition.

Abstract: A cationic liposome having the effect of inhibition of red blood cell hemolysis induced by saponin is disclosed. More particularly, a composition for inhibiting red blood cell hemolysis by saponin comprising a cationic liposome containing an unsaturated lipid, a composition for immunity enhancement and a composition for drug delivery comprising the composition for inhibiting red blood cell hemolysis by saponin, and a drug delivery carrier and a drug-carrier complex comprising a cationic liposome containing an unsaturated lipid are disclosed. Saponin exhibits a wide range of pharmacological and biological activities, such as anti-inflammatory activity, etc., including strong and effective immunological activity, and thus is effectively used medically and pharmaceutically, but has a disadvantage of causing hemolysis to red blood cells. Although saponin is generally used along with cholesterol, etc.

Abstract: The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.

Abstract: The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.

Abstract: The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator.

Abstract: The present invention relates to an immunity enhancing composition including an immune response modulator having a novel structure and, more specifically, to an immunity enhancing composition and a use of the same, wherein the immunity enhancing composition includes a lipopolysaccharide (LPS) analogue with reduced toxicity, and a cationic liposome. The present invention overcomes the physicochemical instability of a liposome, is advantageous in terms of production, transportation, and storage, and improves stability, thus being beneficial as an immune delivery system. In addition, the present invention includes an immune response modulator, and a cationic liposome, and thus exhibits an enhanced immunity-improving effect compared to the case in which an immune response modulator is used alone.

Abstract: Disclosed are peptides for inhibiting mdm2 (mouse double minute 2) and a pharmaceutical composition comprising the same.

Abstract: Disclosed are peptides for inhibiting mdm2 (mouse double minute 2) and a pharmaceutical composition comprising the same.